ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2575

Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening
Abstract Number: 2434

Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response
Abstract Number: 2239

Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials
Abstract Number: 1400

Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
Abstract Number: 1737

ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA
Abstract Number: 0374

Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry
Abstract Number: 1458

Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Abstract Number: 0070

Activation of Joint CD8+ TRM Localize Autoantibody Mediated Arthritis
Abstract Number: 0882

Activation of Ovarian Cancer G-Protein Coupled Receptor (OGR1) Attenuates Chondrocytes Inflammation via ERK1/2 Signaling Pathways in an in Vitro Model of Osteoarthritis
Abstract Number: 0366

Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis
Abstract Number: 1292

Active Rheumatoid Arthritis Patients Exhibit an Altered Serum Lipidomic Profile Directly Linked to Disease Activity, Which Is Reversed by Biologic and Targeted Synthetic DMARD
Abstract Number: 0257

Activity of IgG4-related Disease Differs Depending on the Presence or Absence of Concomitant Hypocomplementemia
Abstract Number: 0474

Acute Cardiovascular Events During Pregnancy and Delivery in Patients with Autoimmune Rheumatic Diseases (ARDs): An Analysis of National Inpatient Sample
Abstract Number: 0722

Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies
Abstract Number: 1527

Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients

« Previous Page
1
…
6
7
8
9
10
…
177
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].